Wormser Freres Gestion Has $9.66 Million Stake in Stryker Corporation $SYK

Wormser Freres Gestion boosted its position in shares of Stryker Corporation (NYSE:SYK) by 3.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 26,403 shares of the medical technology company’s stock after acquiring an additional 814 shares during the quarter. Stryker accounts for 5.9% of Wormser Freres Gestion’s portfolio, making the stock its 4th biggest holding. Wormser Freres Gestion’s holdings in Stryker were worth $9,661,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Elefante Mark B bought a new stake in Stryker during the fourth quarter valued at approximately $337,000. Mogy Joel R Investment Counsel Inc. raised its position in Stryker by 3.4% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company’s stock worth $36,561,000 after acquiring an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. boosted its stake in shares of Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company’s stock worth $65,096,000 after acquiring an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in shares of Stryker during the 1st quarter valued at $1,840,000. Finally, Mar Vista Investment Partners LLC raised its holdings in Stryker by 10.2% in the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock worth $33,572,000 after purchasing an additional 8,353 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is owned by company insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $392.0050 on Thursday. The firm has a market cap of $149.87 billion, a price-to-earnings ratio of 51.92, a P/E/G ratio of 2.83 and a beta of 0.91. The firm has a fifty day moving average price of $387.09 and a 200 day moving average price of $379.54. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same quarter in the prior year, the firm posted $2.81 EPS. Stryker’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio is currently 44.50%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Wells Fargo & Company upped their price target on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Evercore ISI increased their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Friday, July 18th. Citigroup reiterated a “buy” rating and issued a $455.00 price target (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Truist Financial set a $415.00 price objective on shares of Stryker and gave the company a “hold” rating in a research report on Monday, August 4th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average target price of $430.10.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.